## HSIC: Henry Schein, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 0.6% below STRENGTH zone (4.0-10.0%); PEG 1.73 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-4.5% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($73.58)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 9
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Henry Schein expects to appoint next CEO by mid-January (HSIC:NASDAQ)**
- Source: Seeking Alpha | 20251223T213005 | Neutral | Relevance: 100%
- Henry Schein (HSIC) announced that it anticipates appointing its new CEO by mid-January. The company's lead director, Philip A. Laskawy, expressed satisfaction with the progress made in the CEO search. This announcement indicates the culmination of their search efforts is near.

**2. Henry Schein Provides Update on CEO Search Process**
- Source: The AI Journal | 20251223T210843 | Neutral | Relevance: 100%
- Henry Schein, Inc. announced that it expects to appoint its next CEO by mid-January 2026. Lead Director Philip A. Laskawy stated that the search process is nearing completion, with Stanley Bergman continuing as CEO and Chairman until a successor is named to ensure a smooth transition. The company has evaluated highly qualified candidates and anticipates making a formal announcement soon.

**3. Henry Schein Provides Update on CEO Search Process**
- Source: Business Wire | 20251223T210805 | Neutral | Relevance: 100%
- Henry Schein, Inc. announced that it expects to appoint its next CEO by mid-January 2026. Philip A. Laskawy, Lead Director, stated that the search process is nearing completion and a final decision will be made by mid-January, with current CEO Stanley Bergman continuing in his role until then to ensure a smooth transition.

**4. Henry Schein Updates Multiple Financing Agreements With Major Lenders**
- Source: TradingView â€” Track All Markets | 20251223T120813 | Bullish | Relevance: 100%
- Henry Schein (HSIC) has amended four private placement shelf and note facilities with major institutional investors including Prudential, New York Life, MetLife, and Corebridge. These amendments extend the termination date of each facility to December 19, 2028, and update financial definitions and covenants. The purpose is to sustain diversified access to private placement financing and enhance financial flexibility for ongoing operations and strategic initiatives.

**5. Henry Schein (HSIC): Revisiting Valuation After Q3 2025 Earnings Beat and Upgraded Guidance**
- Source: Sahm | 20251221T140807 | Somewhat-Bullish | Relevance: 100%
- Henry Schein (HSIC) experienced an 11% stock jump following its Q3 2025 earnings beat and upgraded guidance, contributing to strong 3-month and 1-year returns. Despite this momentum, the stock is currently trading near Wall Street's target, with a "fair value" according to Simply Wall St. close to its current price, suggesting it is "about right" rather than significantly undervalued, though analysts offer a range of price targets.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $86 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.00M) |
| Sells | 5 ($0.15M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 64.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Kohlberg Kravis Robe: 13.3% (0.0%)
- JPMORGAN CHASE & CO: 10.6% (+98.6%)
- Vanguard Group Inc: 10.2% (-7.2%)
- Artisan Partners Lim: 5.8% (+5.7%)
- Blackrock Inc.: 5.7% (-8.6%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-4.5% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.73 elevated, pricing in significant growth expectations. Institutional flow bullish (5 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.3B |
| Beta | 0.89 |
| 52W Range | $60.56 - $82.49 |
| Short Interest | 6.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.73 |
| Forward P/E | 14.5 |
| Current P/E | 15.6 |
| YoY Growth | 7.6% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 5.1% to 0.6% (-4.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.4pp (needs >4.0% for momentum thesis). MRS_5 (-2.2%) diverging from MRS_20 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: -MTL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.60% (CS: 61) | Neutral |
| RSI_14 | 60.6 | Neutral |
| MACD Histogram | -0.05 | Bearish |
| vs SMA20 | 1.016x | Above |
| vs SMA50 | 1.081x | Above |
| vs SMA200 | 1.103x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $76.50
- **Stop Loss:** $73.58 (3.8% risk)
- **Target:** $79.42 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 410
- **Position Value:** $31,365.00
- **Portfolio %:** 31.36%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-02-24 (Est: $1.30)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.28 | $1.38 | +7.9% |
| 2025Q2 | $1.19 | $1.10 | -7.6% |
| 2025Q1 | $1.11 | $1.15 | +3.6% |
| 2024Q4 | $1.21 | $1.19 | -1.6% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*